Börsch G, Schmidt G, Hopmann G, Surmann T, Sabin G, Ricken D
Klin Wochenschr. 1984 Oct 15;62(20):998-1000. doi: 10.1007/BF01728432.
Seven further cases with n-propyl-ajmaliumbitartrate (NPAB)-associated liver damage observed between 1976 and 1980 in two collaborating institutions are reported. The cause/effect relationship could be classified as probable in three cases and as potential in the remaining four patients. No drug rechallenge was carried out. In the clinical management, definite exclusion of biliary tract obstruction had a clear priority over histologic documentation of the degree of the transient liver damage. Follow-up data after 2 years 8 months to 5 years 9 months by personal reinvestigation of three patients and by questionnaire to family physicians and patients in the remaining four cases gave no clinical or serologic indication of persisting or relapsing liver damage. Liver biopsies were not considered to be warranted in the follow-up of these asymptomatic patients with normal liver function tests.
报告了1976年至1980年间在两个合作机构中观察到的另外7例与重酒石酸正丙基阿马林(NPAB)相关的肝损伤病例。因果关系在3例中可归类为可能,在其余4例患者中可归类为潜在。未进行药物再激发试验。在临床管理中,明确排除胆道梗阻比短暂性肝损伤程度的组织学记录具有明显的优先性。通过对3例患者进行个人复查以及对其余4例患者向家庭医生和患者进行问卷调查,在2年8个月至5年9个月的随访数据中,未发现持续或复发肝损伤的临床或血清学迹象。对于这些肝功能测试正常的无症状患者,随访时不认为有必要进行肝活检。